Andere talen BrightPath Biotherapeutics Co., Ltd.

Aandelen

4594

JP3274140007

Vertraagde tijd Japan Exchange Andere beurzen 05:53:11 14-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
57 ^JPY	0,00%		-3,39%	-34,48%

2022	Brightpath Biotherapeutics kondigt preklinische gegevens aan over BP1209	CI
2018	Brightpath Biotherapeutics Co, Ltd. Rapporteert Geconsolideerde Winstresultaten voor de Zes Maanden Eindigend op 30 September, 2018; Geeft Geconsolideerde Winstrichtlijnen voor het Jaar Eindigend op 31 Maart, 2019	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥5.1678 million in funding from Macquarie Group Limited	30/11
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥5.1678 million in funding from Macquarie Group Limited	14/11
BrightPath Biotherapeutics Co., Ltd.(TSE:4594) dropped from S&P Global BMI Index	19-09-22
BrightPath Biotherapeutics Presents Data on Personalized Neoantigen Cancer Vaccine	14-04-22
BrightPath Biotherapeutics Presents Data on Antibody for Cancer Treatment	14-04-22
BrightPath Biotherapeutics : Presents Preclinical Data on a CD73 antagonist antibody at AACR 2022	13-04-22
BrightPath Biotherapeutics : Presents New Data on Personalized Neoantigen Vaccine at AACR 2022	13-04-22
Brightpath Biotherapeutics Announces Preclinical Data on BP1209	13-04-22
BrightPath Biotherapeutics : Presents New Data on Preclinical Data on BP2301(HER2 CAR-T) at AACR 2022	11-04-22
BrightPath Biotherapeutics : Presents New Data on Personalized Neoantigen Vaccine at AACR 2022	11-04-22
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥1.427175 billion in funding from Macquarie Bank Limited, Investment Arm	01-02-22
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥1.427175 billion in funding from Macquarie Bank Limited, Investment Arm	14-01-22
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥0.585974 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	23-04-20
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥0.585974 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	07-04-20
Brightpath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2018; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2019	09-11-18
Brightpath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2018; Provides Earnings Guidance for the Year Ending March 31, 2018	10-08-18
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended March 31, 2018; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2019	11-05-18
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the Third Quarter Ended December 31, 2017; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2018	14-02-18
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥12.1744 million in funding from Credit Suisse Securities Limited, Investment Arm	08-12-17
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥12.17 million in funding from Credit Suisse Securities Limited, Investment Arm	22-11-17

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen BrightPath Biotherapeutics Co., Ltd.

Aandelen

4594

JP3274140007

Andere talen

Filters